血清补体系统激活因子、游离雌三醇及同型半胱氨酸水平对子痫前期的预测价值

卢昭昭 ,  孙玉娟 ,  郑金鑫 ,  王会娟 ,  王君

中国医科大学学报 ›› 2026, Vol. 55 ›› Issue (7) : 639 -643.

PDF (424KB)
中国医科大学学报 ›› 2026, Vol. 55 ›› Issue (7) : 639 -643. DOI: 10.12007/j.issn.0258‐4646.2026.07.012
论著

血清补体系统激活因子、游离雌三醇及同型半胱氨酸水平对子痫前期的预测价值

作者信息 +

Predictive value of serum complement system activator,unconjugated estriol,and homocysteine levels for preeclampsia

Author information +
文章历史 +
PDF (434K)

摘要

目的 探讨孕早期血清补体系统激活因子、游离雌三醇 (uE3) 及同型半胱氨酸 (Hcy) 水平对子痫前期 (PE) 的预测价值。方法 选取2023年11月至2024年11月间于山东第二医科大学附属医院产前检查并分娩的646例孕妇,于孕11~13+6周常规产前检查时检测血清Hcy、uE3水平,同时检测补体系统激活因子[补体成分3 (C3) 和B因子]。根据孕20周后PE发生情况,将研究对象分为PE组 (n = 56) 和对照组 (n = 590)。比较2组孕妇的一般临床资料、Hcy、uE3及补体系统激活因子水平,并分析PE的独立危险因素。分析各项指标及联合指标对PE的预测价值,构建列线图预测模型,并进行预测和内部验证。结果 2组孕妇年龄、胎龄、生育史及PE史比较无统计学差异 (P > 0.05)。与对照组相比,PE组收缩压、舒张压、血清Hcy、C3和B因子水平升高,妊娠周期及新生儿体重、uE3水平降低 (均P < 0.05)。多因素logistic回归显示,uE3是PE的独立保护因素 (OR = 0.80,95%CI:0.71~0.88),Hcy (OR = 3.531,95%CI:2.35~5.31)、C3 (OR = 1.04,95%CI:1.02~1.06) 和B因子 (OR = 1.03,95%CI:1.02~1.05) 均为PE的独立危险因素。受试者操作特征曲线分析显示,血清uE3、Hcy、C3和B因子截断值分别为1.68 ng/mL、7.44 μmol/L、136.25 mg/dL和326.90 mg/L时,预测PE的灵敏度分别为0.66、0.82、0.72和0.85,特异度分别为0.91、0.86、0.75和0.63; 上述指标联合预测效能更佳,曲线下面积为0.97,灵敏度为0.90,特异度为0.91。列线图预测模型实际校准曲线与理论参考线及完美拟合线吻合度良好,其一致性统计量达0.97 (95%CI:0.65~0.98) 。结论 孕早期血清Hcy、uE3以及补体系统激活因子联合检测对PE具有较好的预测价值,构建的PE风险列线图可为临床早期筛查或预测PE提供参考。

Abstract

Objective To explore the predictive value of serum unconjugated estriol (uE3),homocysteine (Hcy) and complement system activator levels for preeclampsia (PE) during early pregnancy. Methods This study included 646 pregnant women who received prenatal care at the Affiliated Hospital of Shandong Second Medical University between November 2023 and November 2024. Serum Hcy and uE3 levels were measured during routine prenatal examination at 11 to 13+6 weeks of gestation,and the complement system activators C3 and factor B were detected. Depending on whether PE occurred after 20 weeks of gestation,women were divided into the PE group (n = 56) and control group (n = 590). The general clinical data,Hcy,uE3,and complement system activating factor levels of the two groups were compared,and the independent risk factors for PE were analyzed. Receiver operating characteristic (ROC) curves were used to analyze the predictive value of each index and the combined index for PE. PE risk nomogram prediction model and calibration curves were used for prediction and internal verification,respectively. Results There were no significant differences in maternal age,gestational age at detection,reproductive history,or history of PE between the PE and control groups (P > 0.05). The systolic and diastolic blood pressure measurements in the PE group were significantly elevated compared with that in the control group. Additionally,the gestational age at the time of delivery and neonatal birth weight were notably lower in the PE group than in the control group. Furthermore,serum levels of Hcy,complement component C3,and factor B were significantly higher in the PE group than in the control group. In contrast,the concentration of uE3 was significantly lower in the PE group. This suggested that uE3 was an independent protective factor against this condition (OR = 0.80,95%CI:0.71-0.88). In contrast,elevated levels of Hcy,C3,and factor B were identified as independent risk factors for the development of PE (OR = 3.53,95%CI:2.35-5.31; OR = 1.04,95%CI:1.02-1.06; OR = 1.03,95%CI:1.02-1.05,respectively). ROC curve analysis showed that the cutoff values of serum uE3,Hcy,C3,and factor B were 1.68 ng/L,7.44 μmol/L,136.25 pg/dL,and 326.9 mg/L,respectively,and the sensitivity thresholds for predicting PE was 0.66,0.82,0.72,and 0.85,respectively,and specificity thresholds were 0.91,0.86,0.75,and 0.63. The combined prediction performance of the above indicators was better,the area under the curve was 0.97,sensitivity was 0.90,and specificity was 0.91. Internal validation showed that the calibration curve of the nomogram prediction model was close to the original curve and the ideal curve,and the consistency index was 0.97 (95%CI:0.65-0.98),indicating that the model had a high degree of fit. Conclusion A PE risk nomogram based on serum Hcy,uE3,and complement system activating factors in early pregnancy has a good predictive value,and can be used as a reference for early clinical screening or prediction of PE.

关键词

子痫前期 / 游离雌三醇 / 同型半胱氨酸 / 补体系统激活因子 / 预测价值

Key words

preeclampsia / unconjugated estriol / homocysteine / complement system activator / predictive value

引用本文

引用格式 ▾
卢昭昭,孙玉娟,郑金鑫,王会娟,王君. 血清补体系统激活因子、游离雌三醇及同型半胱氨酸水平对子痫前期的预测价值[J]. 中国医科大学学报, 2026, 55(7): 639-643 DOI:10.12007/j.issn.0258‐4646.2026.07.012

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

田飞,刘玉芳,李保卫,等. 血清PLGF/sFlt-1联合胎盘3D-PDI对子痫前期的预测价值 [J]. 中国医科大学学报,2024,53 (2):136-141. DOI:10.12007/j.issn.0258-4646.2024.02.008.

[2]

姜海利,李金皎,贾音,等. 子痫前期孕妇产时中转剖宫产的临床特征和危险因素 [J]. 中国医科大学学报,2021,50 (10):885-889. DOI:10.12007/j.issn.0258-4646.2021.10.004.

[3]

BROWNFOOT F,ROLNIK DL. Prevention of preeclampsia [J]. Best Pract Res Clin Obstet Gynaecol,2024,93:102481. DOI:10.1016/ j.bpobgyn.2024.102481.

[4]

ROBERTS JM. Preeclampsia epidemiology (ies) and pathophysiology (ies) [J]. Best Pract Res Clin Obstet Gynaecol,2024,94:102480. DOI:10.1016/j.bpobgyn.2024.102480.

[5]

QIN WY,HU XH,FU CY,et al. Estimation of homocysteine concen tration as an indicator of foetal death in pregnant Chinese women with preeclampsia:a case-control study [J]. J Clin Lab Anal,2022,36 (4):e24312. DOI:10.1002/jcla.24312.

[6]

MAGED AM,SAAD H,MESHAAL H,et al. Expression of concern:maternal serum homocysteine and uterine artery doppler as predic tors of preeclampsia and poor placentation [J]. Arch Gynecol Obstet, 2024,309 (6):2953. DOI:10.1007/s00404-024-07491-5.

[7]

HUANG TH,BEDFORD HM,RASHID S,et al. Modified multiple marker aneuploidy screening as a primary screening test for preec lampsia [J]. BMC Pregnancy Childbirth,2022,22 (1):190. DOI:10.1186/s12884-022-04514-4.

[8]

ZHANG WY,LIANG HP. The role of serum markers PAPP-a β-hCG,AFP,and uE3 in predicting the risk of preeclampsia in early,middle, and late pregnancy [J]. Technol Health Care,2023,31 (3):1027-1037. DOI:10.3233/thc-220523.

[9]

BALDUIT A,AGOSTINIS C,MANGOGNA A,et al. Systematic review of the complement components as potential biomarkers of pre-eclampsia:pitfalls and opportunities [J]. Front Immunol,2024, 15:1419540. DOI:10.3389/fimmu.2024.1419540.

[10]

HART NR. Paradoxes:cholesterol and hypoxia in preeclampsia [J]. Biomolecules,2024,14 (6):691. DOI:10.3390/biom14060691.

[11]

GAIDAY A,TUSSUPKALIYEV A,BERMAGAMBETOVA S,et al. Prognostic role of increased serum homocysteine concentration in preeclampsia [J]. Hypertens Pregnancy,2021,40 (2):118-123. DOI:10.1080/10641955.2021.1884257.

[12]

ALVESTAD S,HUSEBYE ESN,CHRISTENSEN J,et al. Folic acid and risk of preterm birth,preeclampsia,and fetal growth restriction among women with epilepsy:a prospective cohort study [J]. Neurolo gy,2022,99 (6):e605-e615. DOI:10.1212/wnl.0000000000200669.

[13]

ZHANG CH,HU JJ,WANG X,et al. High level of homocysteine is associated with pre-eclampsia risk in pregnant woman:a me ta-analysis [J]. Gynecol Endocrinol,2022,38 (9):705-712. DOI:10.1080/09513590.2022.2110233.

[14]

ZHENG JY,ZHANG L,ZHOU Y,et al. Development and evaluation of a nomogram for adverse outcomes of preeclampsia in Chinese pregnant women [J]. BMC Pregnancy Childbirth,2022,22 (1):504. DOI:10.1186/s12884-022-04820-x.

[15]

张翼,刘兴会. 子痫前期的主要生物标志物预测指标及其评价 [J]. 实用妇产科杂志,2021,37 (11):803-807.

[16]

詹晓华,冯泰山,吕靖. 妊娠早中期孕母血清中PAPP-A、β-hCG、AFP、uE3联合预测子痫前期的临床价值评估 [J]. 中国优生与遗传 杂志,2024,32 (12):2626-2631. DOI:10.13404/j.cnki.cjbhh.2024.12.037

基金资助

山东省医药卫生科技项目(202305020732)

AI Summary AI Mindmap
PDF (424KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉